[Federal Register Volume 71, Number 164 (Thursday, August 24, 2006)]
[Notices]
[Pages 50072-50077]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 06-7127]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[FDA 225-06-8403]


Memorandum of Understanding Between the U.S. Food and Drug 
Administration, the National Cancer Institute, and the National 
Institute of Standards and Technology

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The purpose of this Memorandum of Understanding (MOU) is to 
set forth an agreement between the National Cancer Institute (NCI), the 
National Institute of Standards and Technology (NIST), and the Food and

[[Page 50073]]

Drug Administration (FDA) (collectively ``the Parties'', or 
individually as a ``Party'') regarding the roles, responsibilities, and 
financial commitments of each Party relating to the collaboration 
through working groups and steering committees to develop strategic 
plans, set priorities, and leverage resources and expertise from 
multiple sources, including the private sector, toward the goal of 
facilitating the development of nanotechnologies that constitute novel 
research tools and safer, more effective cancer therapies by 
establishing a framework for effective risk identification, assessment 
and evaluation of emerging products based on nanotechnology. This 
collaboration among the Parties will be focused primarily on the 
Nanotechnology Characterization Laboratory and directly related 
activities.

DATES: The agreement became effective June 22, 2006.

FOR FURTHER INFORMATION CONTACT:
For FDA: Wendy R. Sanhai, Senior Scientific Advisor, Office of the 
Commissioner (HF-18), Food and Drug Administration, 5600 Fishers Lane, 
Rockville, MD 20857, 301-827-7867, FAX: 301-443-9718.
For NCI: Gregory J. Downing, Director, Office of Technology and 
Industrial Relations, Office of the Director, National Cancer 
Institute, 31 Center Dr., rm. 10A52, Bethesda, MD 20892, 301-496-1550, 
FAX: 301-496-7807.
For NIST: Debra Kaiser, Chief, Ceramics Division, Materials Science and 
Engineering Laboratory, National Institute of Standards and Technology, 
100 Bureau Dr., Stop 8522, Gaithersburg, MD 20899, 301-975-6119, FAX: 
301-975-5334.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 20.108(c), which 
states that all written agreements and MOUs between FDA and others 
shall be published in the Federal Register, the agency is publishing 
notice of this MOU.

    Dated: August 16, 2006.
Jeffrey Shuren,
Assistant Commissioner for Policy.
BILLING CODE 4160-01-S
[GRAPHIC] [TIFF OMITTED] TN24AU06.025


[[Page 50074]]


[GRAPHIC] [TIFF OMITTED] TN24AU06.026


[[Page 50075]]


[GRAPHIC] [TIFF OMITTED] TN24AU06.027


[[Page 50076]]


[GRAPHIC] [TIFF OMITTED] TN24AU06.028


[[Page 50077]]


[GRAPHIC] [TIFF OMITTED] TN24AU06.029

[FR Doc. 06-7127 Filed 8-23-06; 8:45 am]
BILLING CODE 4160-01-C?>